Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2023

  1. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2019

  1. Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study

    Journal of Cardiovascular Electrophysiology, Vol. 30, Núm. 8, pp. 1231-1240

  2. Circulating long noncoding RNA LIPCAR Predicts heart failure outcomes in patients without chronic kidney disease

    Hypertension, Vol. 73, Núm. 4, pp. 820-828

  3. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation

    Journal of the American College of Cardiology, Vol. 73, Núm. 12, pp. 1398-1410

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  3. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  4. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome

    Journal of Hypertension, Vol. 35, Núm. 4, pp. 853-861

2016

  1. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure

    Journal of the American College of Cardiology, Vol. 67, Núm. 3, pp. 251-260

  2. Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients

    Clinical Science, Vol. 130, Núm. 23, pp. 2139-2149

2015

  1. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

2013

  1. A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

    Antioxidants and Redox Signaling, Vol. 19, Núm. 14, pp. 1607-1618

  2. Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis

    Clinical Science, Vol. 125, Núm. 6, pp. 291-300

2012

  1. Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats

    Oxidative Medicine and Cellular Longevity

2011

  1. Genetic remodeling and cardiovascular disease

    Oxidative Stress: A Focus on Cardiovascular Disease Pathogenesis (Nova Science Publishers, Inc.), pp. 95-109

  2. HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia

    Cardiovascular Research, Vol. 92, Núm. 2, pp. 247-255

2010

  1. CYBA gene variants as biomarkers for coronary artery disease

    Drug News and Perspectives, Vol. 23, Núm. 5, pp. 316-324

  2. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950